Edition:
United States

Alere Inc (ALR.N)

ALR.N on New York Stock Exchange

49.17USD
28 Apr 2017
Change (% chg)

$0.07 (+0.14%)
Prev Close
$49.10
Open
$49.16
Day's High
$49.24
Day's Low
$49.06
Volume
306,612
Avg. Vol
170,227
52-wk High
$49.40
52-wk Low
$31.47

ALR.N

Chart for ALR.N

About

Alere Inc. is a provider of health information through diagnostic tests. The Company's segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals... (more)

Overall

Beta: 0.56
Market Cap(Mil.): $4,277.92
Shares Outstanding(Mil.): 87.00
Dividend: --
Yield (%): --

Financials

  ALR.N Industry Sector
P/E (TTM): -- 51.37 30.08
EPS (TTM): -0.88 -- --
ROI: -1.74 6.70 13.25
ROE: -5.16 10.65 14.41

BRIEF-Alere launches the first-ever rapid test to screen malaria infection in asymptomatic individuals

* Alere launches the Alere malaria AG P.F, the first-ever rapid test to screen malaria infection in asymptomatic individuals Source text for Eikon: Further company coverage:

Apr 25 2017

BRIEF-Alere Inc enters into third amendment

* Alere Inc - on April 24, co entered into third amendment, dated as of April 24, to secured credit agreement, dated as of June 18, 2015

Apr 24 2017

Abbott sees Alere as challenging 'fixer-upper' after revised deal

Abbott Laboratories said it was looking to close the recently revised deal to buy Alere Inc in the coming months, calling the diagnostics company "a bit of a fixer-upper".

Apr 19 2017

UPDATE 3-Abbott sees Alere as challenging "fixer-upper" after revised deal

* Closing of new Alere deal is a little unpredictable - CFO (Adds conference call details; Updates shares)

Apr 19 2017

BRIEF-Abbott CFO says "We're not going to really be in a good position to give a lot of detailed guidance (on Alere) until minimum Q4" - Conf Call

* Abbott CEO says "the acquisition of Alere will significantly expand our diagnostics presence and leadership in that space" - Conf Call

Apr 19 2017

BRIEF-Alere concluded its financial statements as of Dec 31, 2015 and 2014 should not be relied upon

* Alere - On April 12, concluded co's financial statements and other financial data as of December 31, 2015 and 2014 should not be relied upon - SEC filing

Apr 17 2017

Abbott agrees to buy Alere at lower price from earlier offer

Diversified healthcare company Abbott Laboratories on Friday agreed to buy Alere Inc at a lower price than it had previously offered, after raising concerns about the accuracy of various representations, warranties and covenants made by Alere in the earlier agreement.

Apr 14 2017

UPDATE 4-Abbott agrees to buy Alere at lower price from earlier offer

* Abbott, Alere say they agreed to dismiss respective lawsuits

Apr 14 2017

BRIEF-Abbott and Alere amend terms of merger agreement

* Under amended terms, Abbott will pay $51 per common share to acquire Alere

Apr 14 2017

RPT-Abbott Laboratories to buy Alere for $4.4 bln - FT

April 14 Abbott Laboratories agreed to buy diagnostic-testing company Alere Inc for $4.4 billion, ending a prolonged legal battle over Abbott's plan to buy the company, the Financial Times reported, citing people close to the matter.

Apr 14 2017

More From Around the Web

Competitors

Earnings vs. Estimates